-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Benzinga·05/02/2025 12:26:18
Listen to the news
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.